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A B S T R A C T
Background: The increasing use of transcatheter aortic valve implantation (TAVI) in high-risk patients, 
especially those with ventricular dysfunction, justifies further evaluation of the selection and the results 
of the procedure. A database was used to characterize the profile of patients and evaluate TAVI results 
according to the degree of ventricular dysfunction. 
Methods: This was a longitudinal observational study that included all patients with severe aortic stenosis 
(AoS) submitted to TAVI between 2009 and 2014, comparing those with left ventricular ejection fraction 
(LVEF) ≤ 40% vs. > 40%. The safety and efficacy outcomes were evaluated at 30 days and 1 year. 
Results: Of the 172 patients, 20 (11.6%) had LVEF ≤ 40%. These patients were younger, with a higher 
prevalence of smoking, previous acute myocardial infarction, coronary artery bypass graft surgery, 
permanent pacemaker, and pulmonary artery hypertension. Higher functional classes were also more 
often observed in this group. The group with LVEF ≤ 40% had lower mean aortic valve gradient for an 
equivalent valve area. The procedure success did not differ between groups. There were no differences in 
mortality in coronary and cerebrovascular events, bleeding, vascular complications, and acute renal failure 
in the 30 day and 1 year follow-up. In the LVEF ≤ 40% group, the mean LVEF increased from 31.5 to 45.1% 1 
year after the procedure (p = 0.002).
Conclusions: TAVI in patients with severe AoS and LVEF ≤ 40% does not increase the risk of complications 
and is associated with LVEF improvement.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Published by Elsevier Editora Ltda. 
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 
 
Desfechos de curto e médio prazos de pacientes com e sem disfunção ventricular 
esquerda submetidos ao implante transcateter de prótese valvar aórtica
R E S U M O
Introdução: A utilização crescente do implante transcateter de prótese valvar aórtica (TAVI) em pacientes 
de alto risco, em especial naqueles com disfunção ventricular, justifica uma avaliação mais profunda da 
seleção e dos resultados do procedimento. Utilizamos nosso banco de dados para caracterizar o perfil dos 
pacientes e avaliar os resultados do TAVI de acordo com o grau de disfunção ventricular. 
Métodos: Estudo observacional longitudinal no qual foram incluídos todos os pacientes com estenose 
aórtica (EAo) grave, submetidos ao TAVI entre 2009 e 2014, e comparados àqueles com fração de ejeção do 
ventrículo esquerdo (FEVE) ≤ 40% vs. > 40%. Foram avaliados os desfechos de segurança e eficácia em 30 
dias e 1 ano. 
Resultados: Dentre os 172 pacientes, 20 (11,6%) apresentavam FEVE ≤ 40%. Esses pacientes eram mais jovens, 
com maior prevalência de tabagismo, infarto agudo do miocárdio prévio, cirurgia de revascularização 
miocárdica, marca-passo definitivo e hipertensão arterial pulmonar. Também se observou, nesse grupo, 
maior frequência de classes funcionais mais elevadas. O grupo com FEVE ≤ 40% apresentou menor 
gradiente valvar aórtico médio para área valvar equivalente. As taxas de sucesso do procedimento não 
diferiram entre os grupos. Não foram observadas diferenças na mortalidade, nos eventos coronarianos, 
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cerebrovasculares, sangramentos, complicações vasculares e disfunção renal aguda no acompanhamento 
de 30 dias e 1 ano. No grupo FEVE ≤ 40%, a média da FEVE elevou-se de 31,5 para 45,1% 1 ano após o 
procedimento (p = 0,002). 
Conclusões: O TAVI em pacientes com EAo grave e FEVE ≤ 40% não aumenta o risco de complicações e está 
associado à melhora da FEVE.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Publicado por Elsevier Editora Ltda. 
Este é um artigo Open Access sob a licença de CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Degenerative aortic stenosis (AoS) is the most common valve di-
sease in adults, whose prevalence increases with age, affecting 
approximately 4% of individuals older than 80 years. Data from the 
Instituto Brasileiro de Geografia e Estatística (IBGE) estimates that 
within 20 years, the country will have 14.5 million elderly individu-
als older than 75 years, of whom 400,000 to 650,000 might have de-
generative AoS.1,2
Patients with severe AoS have formal indication for valve repla-
cement, due to the unfavorable prognosis with clinical treatment.3,4 
However, approximately 30% of patients with AoS and surgical in-
dication are not submitted to valve replacement due to advanced 
age, comorbidities, physician or patient's refusal to conventional 
surgical treatment.5 
In the context of patients with symptomatic severe AoS and high 
surgical risk or inoperable patients, the transcatheter aortic valve 
implantation (TAVI) was introduced, and the PARTNER (Placement 
of AoRtic TraNscathetER Valves) trial was the first randomized study 
to show that TAVI was an alternative not inferior to surgery in high 
risk patients (cohort A) and a superior option to clinical treatment in 
those considered inoperable (cohort B).6 More recently, the CoreVal-
ve US Pivotal Trial showed that TAVI may be superior to valve repla-
cement surgery, in terms of reducing mortality in patients with high 
surgical risk (Society of Thoracic Surgeons Predicted Risk of Mortali-
ty - STS PROM ≥ 15%).7 
The increasing use of TAVI in high-risk patients, especially those 
with ventricular dysfunction, justifies further evaluation of proce-
dure selection and outcomes. This institution’s database was used to 
characterize the profile of patients and evaluate TAVI results accor-
ding to the ventricular dysfunction degree. The authors compared 
patients with moderate to severe systolic dysfunction of the left ven-
tricle (LV), defined as left ventricular ejection fraction (LVEF) ≤ 40%, 
with those individuals with LVEF > 40%.
Methods
An observational and longitudinal study was carried out, whi-
ch included all patients with severe, symptomatic AoS submitted 
to TAVI, from January 2009 to June 2014, at Instituto Dante Paz-
zanese de Cardiologia and Hospital do Coração (HCor), both loca-
ted in São Paulo (SP), after the project approval by the Institutional 
Ethics Committee. 
Clinical data were obtained by clinical examination and com-
plementary tests (resting electrocardiography, chest X-ray, trans-
thoracic Doppler echocardiography with protocol for aortic 
complex measurements; computed tomography angiography of 
the heart and total aorta, and cardiac catheterization with coro-
nary angiography). Transesophageal echocardiography was used to 
guide the procedure and detect possible complications due to pros-
thesis implantation.
Data were recorded on appropriate forms, which were developed 
for the study and stored in electronic spreadsheets.
Patient preparation and type of prosthesis used 
All patients were pretreated with 100 mg acetylsalicylic acid and 
300 mg clopidogrel on the day prior to implantation. In patients with 
renal dysfunction, intravenous hydration with 0.9% saline solution 
at a dose of 0.3 to 0.5 mL/kg/hour was started 12 hours before the 
procedure. Additionally, aiming to prevent contrast-induced 
nephropathy, the angiograms required during the procedure were 
obtained with low-osmolarity contrast, with a 50% dilution. 
The self-expanding CoreValve (Medtronic – Minneapolis, USA) 
and Acurate (Symetis – Ecublens, Switzerland) prostheses were 
used, as well as the Edwards Sapien (Edwards Lifesciences – Irvi-
ne, USA) balloon-expandable prosthesis. The choice of prosthesis 
was based on device availability and the operators choice.
The patients were admitted to the intensive care unit after the 
intervention, and on the first day after the procedure, underwent 
laboratory tests, electrocardiogram, and echocardiogram.
Outcomes and definitions
Outcomes and complications were detailed according to the 
standardized and updated definitions of the Valve Academic Resear-
ch Consortium-2 (VARC2).8 Device success was considered a single 
prosthesis implantated in the appropriate place, with no prosthesis-
-patient mismatch, obtaining a mean aortic transvalvular gradient 
< 20 mmHg or peak velocity < 3 m/s, and in the absence of aortic re-
gurgitation equal or greater than moderate – according to transeso-
phageal or transthoracic echocardiography definitions. 
Procedural success and safety (30 days) and efficacy (1 year) 
outcomes were assessed. Stroke was determined by the onset of 
focal or global neurological deficit lasting > 24 hours, or the pre-
sence of a new cerebral infarction area, or bleeding in neuroima-
ging methods, regardless of symptom duration. Hemorrhagic 
complications were divided into: (1) life-threatening bleeding: 
when fatal or overt bleeding occurred in a vital organ (intracra-
nial, intraocular, and pericardial), or bleeding that resulted in 
hypovolemic shock or severe hypotension requiring vasopressors 
or surgery, or overt bleeding with hemoglobin decrease ≥ 5 g/dL 
or that required transfusion of four or more packed red blood 
cells; (2) major bleeding: overt bleeding with decrease in hemo-
globin ≥ 3 g/dL or that required transfusion of two or three pa-
cked red blood cells, or bleeding that required hospitalization or 
surgery; (3) minor bleeding: any significant bleeding (e.g., punc-
ture site hematoma) that did not meet the criteria for life-threa-
tening or major bleeding. 
Vascular complications were classified as major, according to the 
following criteria: occurrence of aortic dissection, aorta or aortic an-
nulus rupture, or LV perforation; diagnosis of vascular injury at the 
femoral puncture site, which resulted in death, major, or life-threa-
tening bleeding; vascular injury that caused visceral ischemia or 
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neurological impairment; non-cerebral distal embolization that re-
quired surgery; need for surgical or percutaneous intervention, whi-
ch led to death, major bleeding, visceral ischemia, or neurological 
impairment; or any documented ipsilateral ischemia. 
Chronic renal failure was determined by the presence of creati-
nine clearance < 50 mL/minute. Acute kidney injury after the pro-
cedure was classified according to Acute Kidney Injury Network 
(AKIN) criteria, being evaluated until the seventh day post-implan-
tation. Kidney injury was categorized as: (a) stage 1: increase of 
0.3 mg/dL or 150 to 200% increase of baseline serum creatinine le-
vel or urine output < 0.5 mL/kg/hour for 6 hours after the procedu-
re; (b) stage 2: increase > 200 to 300% of baseline serum creatinine 
and urine output < 0.5 mL/kg/hour for > 12 hours; (c) stage 3: incre-
ase > 300% of baseline serum creatinine or serum creatinine 
≥ 4.0 mg/dL, associated with an increase of at least 0.5 mg/dL of 
baseline level; urine output < 0.3 mL/kg/hour for 24 hours or anuria 
for more than 12 hours. The presence of pulmonary hypertension 
was determined by the pulmonary artery systolic pressure (mea-
sured by transthoracic echocardiography) > 55 mmHg. 
Statistical analysis 
Continuous variables were described as mean and standard de-
viation, and categorical variables as absolute number and percenta-
ge. Student’s t-test (or the Mann-Whitney test) was used to compare 
continuous variables for independent samples, and the chi-squared 
test or Fisher's exact test was used for categorical variables, as 
appropriate. LVEF comparisons during follow-up were performed 
using Friedman’s test for repeated measures. All analyses were per-
formed using Statistical Package for the Social Science (SPSS) sof-
tware version 19 and R, version 3.1.2. Statistical significance level 
was set at 5%. 
Results
From January 2009 to June 2014, 172 patients were submitted 
to TAVI, distributed into Group 1, comprising patients with LVEF 
≤ 40% (n = 20; 11.6%) and Group 2, comprising patients with LVEF 
> 40% (n = 152). Patients with LVEF ≤ 40% were younger (77.2 ± 8.5 
vs. 83.2 ± 6.0 years; p = 0.002), had higher prevalence of smoking 
(35.0% vs. 15.1%; p = 0.03), previous acute myocardial infarction 
(45.0% vs. 17.8%; p = 0.005), coronary artery bypass grafting sur-
gery (50.0% vs. 19.1%; p = 0.002), permanent pacemaker (30.0% vs. 
7.0%; p = 0.006), and pulmonary artery hypertension (60.0% vs. 
27.6 %; p = 0.003). Group 1 also had increased frequency of higher 
functional classes and higher serum creatinine levels (1.37 ± 0.36 
vs. 1.20 ± 0.46 mg/dL; p = 0.03). In the pre-TAVI evaluation, EuroS-
CORE I (30.6% ± 11.8% vs. 20.9% ± 11.3%; p < 0.001), EuroSCORE II 
(14.4% ± 11.1% vs. 7.0 ± 11.3%, p < 0.001), and STS score for mortali-
ty (8.0 ± 5.8 vs. 6.0 ± 3.4; p = 0.003) were higher for the group with 
LVEF ≤ 40% (Table 1). 
The pre-procedure echocardiogram showed mean LVEF of 31.5 ± 
3.9% in Group 1 and 61.5 ± 8.4% in Group 2. Group 1 had higher left 
Table 1
Basal clinical data.
Group  1 
n = 20
Group  2 
n = 152
p-value
Age, years 77.2 ± 8.5 83.2 ± 6.0 0.002
Female gender, n (%) 13 (65.0) 66 (43.4) 0.10
BMI, kg/m2 26.4 ± 4.7 26.2 ± 4.2 0.99
Diabetes mellitus, n (%) 9 (45.0) 48 (31.6) 0.23
Using insulin 2 (10.0) 11 (7.2) 0.66
Arterial hypertension, n (%) 14 (70.0) 128 (84.2) 0.12
Dyslipidemia, n (%) 8 (40.0) 105 (69.1) 0.01
Smoking, n (%) 7 (35.0) 23 (15.1) 0.03
Previous myocardial infarction, n (%) 9 (45.0) 27 (17.8) 0.005
Previous CABG, n (%) 10 (50.0) 29 (19.1) 0.002
Previous PCI, n (%) 6 (30.0) 41 (27) 0.78
Previous ischemic stroke, n (%) 0 10 (6.6) 0.24
COPD, n (%) 3 (15.0) 20 (13.2) 0.82
Creatinine pre, mg/dL 1.37 ± 0.36 1.20 ± 0.46 0.03
Creatinine clearance pre, mL/kg/h 44.5 ± 15.5 46.6 ± 21.6 > 0.99
Hemodialysis, n (%) 0 2 (1.3) 0.61
Peripheral vascular disease, n (%) 2 (10.0) 40 (26.3) 0.11
Carotid lesion > 50%, n (%) 5 (25.0) 26 (17.1) 0.39
Coronary lesion > 50%, n (%) 15 (75.0) 80 (52.6) 0.06
Permanent pacemaker, n (%) 6 (30.0) 11 (7.0) 0.006
Implantable cardioverter defibrillator, n (%) 1 (5.0) 0 0.12
HF–NYHA, n (%) 0.01
I 1 (5.0) 6 (3.9)
II 2 (10.0) 33 (21.7)
III 9 (45.0) 99 (65.1)
IV 8 (40.0) 14 (9.2)
Syncope/pre-syncope, n (%) 7 (35.0) 38 (25.0) 0.34
Angina CCS class 4, n (%) 2 (10.0) 11 (7.3) 0.67
PAH ≥ 55 mmHg, n (%) 12 (60.0) 42 (27.6) 0.003
CAD, n(%) 0.24
One-vessel 9 (45.0) 38 (25.0)
Two-vessel 3 (15.0) 24 (15.8)
Three-vessel 2 (10.0) 13 (8.6)
Aortic valve, n (%) 0.31
Tricuspid valve 18 (90.0) 145 (95.4)
Bicuspid valve 2 (10.0) 7 (4.6)
EuroSCORE I 30.6 ± 11.8 20.9 ± 11.3 0.001
EuroSCORE II 14.4 ± 11.1 7.0 ± 11.3 0.001
STS morbidity score 37.4 ± 16.7 27.3 ± 9.2 0.22
STS mortality score 8.0 ± 5.8 6.0 ± 3.4 0.003
Group 1: left ventricular ejection fraction ≤ 40%; Group 2: left ventricular ejection fraction > 40%. BMI: body mass index; CABG: coronary artery bypass graft surgery; PCI: percutaneous coronary intervention; 
COPD: chronic obstructive pulmonary disease; HF: heart failure; NYHA: New York Heart Association; PAH: pulmonary artery hypertension; CAD: coronary artery disease; STS: Society of Thoracic Surgeons. 
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atrial diameter (48.5 ± 6.3 vs. 44.3 ± 5.0 mm; p = 0.003) and higher LV 
end-diastolic diameter (60.8 ± 8.1 vs. 49.3 ± 5.5 mm; p < 0.001). The 
valve area evaluation through the continuity equation showed an 
equivalent area in both groups (0.66 ± 0.13 vs. 0.67 ± 0.15 cm2; p = 
0.75), but lower maximum (67.7 ± 23.0 vs. 90.1 ± 21.3 mmHg, 
p < 0.001) and mean systolic transaortic gradients (40.9 ± 14.2 vs. 
55.7 ± 14.3 mmHg; p < 0.001) for the group with LVEF ≤ 40%. The 
aortic valve annulus measurement and the evaluation of the pre-
-aortic regurgitation did not differ between the groups (Table 2). 
A total of 84 CoreValve prostheses, 52 Edwards Sapien prosthe-
ses, and 36 Acurate prostheses were implanted. There was a signifi-
cant decrease in transvalvular gradients in both groups. Procedural 
success was similar in both groups (90.0% vs. 93.4%; p = 0.57). In 
Group 1, all the procedures were performed using the femoral ac-
cess, while in Group 2, the femoral (86.8%), transaortic (6.6%), tran-
sapical (5.3%), subclavian artery (0.7%), and iliac artery accesses 
(0.7%) were used (Table 3). 
At 30 days and 1 year, the cumulative mortality rates were 12.8 
and 16.9%, respectively; for stroke, they were 2.9 and 2.9%; for major 
vascular complications, 7.0 and 7.6%; for major or life-threatening 
bleeding, 24.4 and 25.6%, showing no significant differences betwe-
en the two groups. The outcomes of emergency surgery, acute renal 
failure, acute respiratory failure, atrioventricular block, conduction 
disorders, permanent pacemaker, infections, and endocarditis at 30 
days and 1 year, were also similar between groups (Table 4). 
The LVEF in Group 1 significantly improved, increasing from 
31.5% pre-procedure to 35.8, 41.8, and 45.1% at 1, 6, and 12 months 
post-procedure, respectively (p = 0.002; Fig. 1).
Discussion
This study showed that left ventricular dysfunction had no signi-
ficant effect on procedural success or the outcomes at 30 days and 1 
year post-TAVI. Data from a Canadian registry (n = 339) also failed to 
demonstrate an adverse impact of left ventricular dysfunction on 
short- and long-term post-procedural clinical outcomes.9 The British 
registry, with a larger number of patients (n = 2,535), showed that 
neither the low LVEF, nor a low gradient affected TAVI success or 30 
day mortality. Long-term survival, however, was reduced in patients 
with low LVEF and low gradient, but not in those with low LVEF and 
high gradient, or normal LVEF and paradoxically low gradient.10 Con-
versely, a German registry (n = 1,302) found increased risk of death 
at 30 days and 1 year for patients with low LVEF associated with low 
flow and low gradient post-TAVI.11
In the present study, patients with LVEF ≤ 40% had favorable re-
sults in the short and medium term, which may reflect the selection 
of patients with preserved cardiac reserve and consequent LVEF re-
covery after TAVI, an effect that has been previously reported.12 In-
deed, the most relevant fact of this study was the significant LVEF 
improvement during the course of 1 year. A recent publication 
Table 2
Pre-procedure echocardiographic data.
Group  1 
n = 20
Group  2 
n = 152
p-value
Left atrium, mm 48.5 ± 6.3 44.3 ± 5.0 0.003
LVDD, mm 60.8 ± 8.1 49.3 ± 5.5 < 0.001
PASP, mmHg 54.0 ± 12.1 47.1 ± 14.2 0.02
Maximum LV-Ao gradient, mmHg 67.7 ± 23.1 90.1 ± 21.3 < 0.001
Mean LV-Ao gradient, mmHg 40.9 ± 14.2 55.7 ± 14.3 < 0.001
Aortic valve area, cm2 0.66 ± 0.13 0.67 ± 0.15 0.75
Aortic annulus, cm2 23.1 ± 1.8 22.4 ± 1.9 0.08
Aortic regurgitation, n (%) 0.48
Absent/minimum 1 (5.0) 15 (9.9)
Mild 16 (80.0) 125 (82.2)
Moderate 3 (15.0) 12 (7.9)
Group 1: left ventricular ejection fraction ≤ 40%; Group 2: left ventricular ejection fraction > 40%. LVDD: left ventricular diastolic diameter; PASP:pulmonary artery systolic pressure; LV: left ventricle; 
Ao: aorta.
Table 3
Procedure data.
Group  1 
n = 20
Group  2 
n = 152
p-value
Vascular access, n (%) 0.56
Femoral 20 (100) 132 (86.8)
Transaortic 0 10 (6.6)
Transapical 0 8 (5.3)
Subclavian 0 1 (0.7)
Iliac 0 1 (0.7)
Type of prosthesis, n (%) 0.39
CoreValveTM 12 (60.0) 72 (47.4)
Sapien 6 (30.0) 46 (30.3)
Acurate 2 (10.0) 34 (22.4)
Mean systolic gradient prea, mmHg 44.7 ± 21.0 69.9 ± 29.4 0.003
Mean systolic gradient posta, mmHg 4.7 ± 6.2 3.9 ± 6.2 0.40
Device success, n (%) 18 (90.0) 144 (94.7) 0.57
Clinical success, n (%) 18 (90.0) 143 (93.4) 0.40
Aortic regurgitation post 0.16
Absent/minimum 8 (40.0) 80 (52.6)
Mild 7 (35.0) 66 (43.4)
Moderate 5 (25.0) 6 (3.9)
Group 1: left ventricular ejection fraction ≤ 40%; Group 2: left ventricular ejection fraction > 40%.  
a Values obtained at the catheterization.
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Table 4
Cumulative 30-day and 1-year outcomes after the procedure.
30-day outcomes 1-year outcomes
Group  1 
n = 20
Group  2 
n = 152
p-value Group  1 
n = 20
Group  2 
n = 152
p-value
Death, n (%) 1 (5.0) 21 (13.8) 0.27 1 (5.0) 28 (18.4) 0.13
Myocardial infarction, n (%) 1 (5.0) 3 (2.0) 0.40 1 (5.0) 4 (2.7) 0.47
Stroke, n (%) 1 (5.0) 4 (2.6) 0.55 1 (5.0) 4 (2.6) 0.55
TIA, n (%) 1 (5.0) 2 (1.3) 0.24 2 (10.0) 2 (1.3) 0.02
Bleeding, n (%) 8 (40.0) 66 (43.4) 0.77 8 (40.0) 68 (44.7) 0.70
Minor 4 (20.0) 28 (18.4) 4 (20.0) 28 (18.4)
Major 4 (20.0) 30 (19.7) 4 (20.0) 30 (19.7)
Life-threatening 0 (0) 8 (5.3) 0 (0) 10 (6.6)
ARF, n (%) 3 (15.0) 38 (25.0) 0.73 4 (20.0) 40 (26.3) 0.86
AKIN 1 2 (10.0) 24 (15.8) 2 (10.0) 24 (15.8)
AKIN 2 0 5 (3.3) 1 (5.0) 5 (3.3)
AKIN 3 1 (5.0) 9 (5.9) 1 (5.0) 11 (7.2)
Vascular complications, n (%) 4 (20.0) 28 (18.4) 0.23 4 (20.0) 29 (19.1) 0.82
Minor 1 (5.0) 19 (12.5) 1 (5.0) 19 (12.5)
Major 3 (15.0) 9 (5.9) 3 (15.0) 10 (6.6)
Infection, n (%) 1 (5.0) 31 (20.4) 0.38 3 (15.0) 36 (23.7) 0.76
Respiratory 1 (5.0) 15 (9.9) 1 (5.0) 18 (12.8)
Vascular 0 2 (1.3) 0 2 (1.3)
Other 0 14 (9.2) 2 (10.0) 16 (10.5)
Acute respiratory failure, n (%) 1 (5.0) 9 (5.9) 0.87 1 (5.0) 10 (6.6) 0.79
Atrioventricular block, n (%) 1 (5.0) 26 (17.1) 0.16 1 (5.0) 28 (18.4) 0.13
Conduction disorder, n (%) 5 (25.0) 53 (34.9) 0.38 6 (30.0) 53 (34.9) 0.67
Permanent pacemaker, n (%) 1 (5.0) 19 (12.5) 0.33 2 (10.0) 23 (15.0) 0.54
Endocarditis, n (%) 0 1 (0.7) 0.72 0 1 (0.7) 0.72
Emergency surgery, n (%) 0 1 (0.7) 0.72 0 1 (0.7) 0.72
TIA: transient ischemic attack; ARF: acute renal failure; AKIN: Acute Kidney Injury Network. 
Figure 1. Evolution of left ventricular ejection fraction (LVEF) after transcatheter aortic 
valve implantation in patients with left ventricular dysfunction during evolution.
showed that patients with significant reduction in ventricular func-
tion (LVEF ≤ 30%) submitted to TAVI showed rapid improvement in 
left ventricular function, as well as functional class improvement.13 
Similarly, the study by Zhao et al. showed that, after removal of the 
left ventricular outflow tract obstruction, patients submitted to 
TAVI showed early recovery of the parameters that evaluated the 
systolic and diastolic functions of the left ventricle, particularly tho-
se with left ventricular dysfunction. Among patients with LVEF < 
50%, LVEF increased from 46 ± 5.7% to 57 ± 4.5% (p = 0.02). Better 
septal performance was also observed, which can be crucial for tho-
se patients with coronary artery disease, in which the septum has an 
important role in maintaining stroke volume.14
Data from studies with surgical patient population and LV dys-
function (LVEF ≤ 30% or NYHA III or IV) demonstrate that the pre-
dictors of systolic function recovery, defined as gain of more than 
10% in LVEF on the seventh day post-intervention, were the cardio-
thoracic index and mean systolic transaortic gradient; the latter 
can be considered an indirect indicator of ventricular function as-
sessment in these patients. Complementarily, patients with LV dys-
function secondary to valvular heart disease (afterload mismatch) 
benefited more than those with primary myocardial dysfunction 
unrelated to AoS.15 
A study published in 2012 suggests a similar situation, in which the 
LV systolic function improves promptly after TAVI, also including pa-
tients with preserved LVEF. This favorable evolution is demonstrated 
by echocardiography through more sensitive methods, such myocar-
dial deformation analysis (strain and speckle tracking). Improvement 
occurs predominantly in the basal and medial LV segments.16 
Current surgical outcomes demonstrate that patients with low-
-flow, low-gradient AoS have better evolution when submitted to 
surgical aortic valve replacement, compared to those managed clini-
cally, after appropriate selection. The mortality found in a recent 
series was estimated at 10%, and the long-term prognosis was much 
better in those submitted to aortic valve replacement. In these pa-
tients, the percutaneous valve replacement strategy could have si-
milar results ,  or even super ior,  by prevent ing the use of 
extracorporeal circulation and prolonged ventilation.17 In this sense, 
Bauer et al. demonstrated that, when compared to the surgical treat-
ment, TAVI showed better recovery of LVEF on the seventh day after 
surgery in patients with left ventricular dysfunction (LVEF < 45%).18 
In addition to the improvement in systolic function parameters, 
diastolic function improvement after TAVI can be observed.19
Study limitations
Firstly, this study reflects the experience of a limited number of 
patients treated at two centers. Secondly, the absence of systolic vo-
lume measurements, LV dimensions, and aortic valve impedance 
prevented the categorization of patients with low flow. Finally, these 
results are limited to the 30 day and 1 year follow-up.
Conclusions
Transcatheter aortic valve implantation showed to be effective 
and safe in patients with moderate to severe left ventricular dys-
function, which may reflect the choice of patients with preserved 
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cardiac reserve and post-procedure ejection fraction recovery. Fur-
ther studies are required to confirm the results found in this chal-
lenging group of patients with severe aortic stenosis and left 
ventricular dysfunction.
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